CLOVER BIO-B: 2024 Annual Report

HKEXApr 17 16:42 · Announcements

Three Leaf Clover Biotech-B (02197.HK) granted 5.964 million stock options and 9.0165 million restricted share units.

On April 2nd, Gelonghui reported that Clover Biotech-B (02197.HK) announced that the Board of Directors declared that on April 2nd, 2025, the company granted a total of 5,964,000 stock options and 9,016,500 restricted share units to several eligible participants in accordance with the terms of the stock option plan and the restricted share unit plan after the initial public offering.

Gelonghui FinanceApr 2 21:48

The performance of Clover Biotech (02197.HK) recorded an annual loss expanded to 0.903 billion RMB, with the auditor expressing an opinion.

Sanlian Biological-B (02197.HK) announced its annual results for the year ending December last year, with a revenue of 38.419 million yuan (RMB, same below), a year-on-year decrease of 2.1%. Losses expanded to 0.903 billion yuan, compared to a loss of 0.139 billion yuan in the same period last year; the loss per share is 0.72 yuan. No dividend is declared. An independent auditor's opinion was issued.

AASTOCKSApr 1 09:36

Clover Biotech-B (02197) announced its annual performance, with a loss of 0.903 billion yuan for the year.

Clover Bio-B (02197) announced its annual results for the year ending December 31, 2024, with revenues of 3841...

Zhitong FinanceMar 31 23:20

CLOVER BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024

HKEXMar 31 22:44 · Announcements

Clover Biopharmaceuticals Begins US Trial for RSV Vaccine SCB-1019

MT NewswiresMar 24 11:56